DexCom, Inc. operates in the healthcare sector, focusing on continuous glucose monitoring systems. The company's stable product lineup and strategic collaborations position it well for future growth. Recent fundamental ratings reflect a positive, though cautious, investor sentiment.
DexCom has a fundamental rating of B+, indicating a solid financial standing with room for growth in certain areas.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 4 | |
| Return on Equity | 5 | |
| Return on Assets | 5 | |
| Debt to Equity | 1 | |
| Price to Earnings | 2 | |
| Price to Book | 1 |
The historical data shows a stable score with slight improvements over time, emphasizing consistent performance in key metrics.
| Date | Overall Score | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| - | 0 | 4 | 5 | 5 | 1 | 2 | 1 |
| 2026-04-27 | 3 | 4 | 5 | 5 | 1 | 2 | 1 |
Analysts forecast a median price target of $86.5, suggesting an upward potential from current levels, with targets ranging between $72 and $95.
| High | Low | Median | Consensus |
|---|---|---|---|
| $95 | $72 | $86.5 | $85 |
The sentiment among analysts is predominantly positive, with a majority recommending buying the stock.
| Recommendation | Count | Visualization |
|---|---|---|
| Strong Buy | 1 | |
| Buy | 41 | |
| Hold | 8 | |
| Sell | 2 | |
| Strong Sell | 0 |
DexCom, Inc. displays a robust fundamental profile, backed by a sound product lineup and strategic partnerships. While it shows solid return metrics, the debt-to-equity and price valuations suggest areas for improvement. With positive analyst sentiments and price targets indicating potential growth, investors might find DexCom a promising opportunity. However, potential risks remain, notably in competitive pressures and market volatility. Continuous monitoring of its financial health and market position is advisable.